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Fumaric acid esters (FAE) have been used for the sys-
temic treatment of psoriasis in Germany for almost 50
years. Recently, it has been shown that dimethylfuma-
rate (DMF) as the main ingredient of the marketed FAE
mixture is a potent inhibitor of the nuclear transcrip-
tion factor NF-jB. DMF was also shown to induce
apoptosis in various cells. Because T cells play a crucial
role in psoriasis pathogenesis, we asked whether DMF
and its main metabolite methylhydrogenfumarate
(MHF) were able to induce apoptosis in these cells. Pur-
i¢ed human T cells were treated with DMF and MHF
(1^20 lg/mL) and stimulated with interleukin 2, anti-
CD3 antibodies or both for 48 h, and apoptosis was sub-
sequently determined by the expression of Apo2.7 as
well as by terminal deoxynucleotide transferase nick
end labeling. The expression of antiapoptotic protein
Bcl-2 was simultaneously determined. The results
showed a dose-and-time dependent up-regulation of
Apo2.7 expression and DNA fragmentation by DMF
preferable in stimulated T cells. MHF and the solvent
dimethyl sulfoxide were without e¡ect. DMF, but not
MHF, led to a concentration-dependent decrease of
Bcl-2 expression in interleukin-2-stimulated T cells.
The data provide evidence that the e¡ect of FAE treat-
ment of psoriasis may at least in part be due to induc-
tion of apoptosis in activated Tcells. Key words: psoriasis/
fumaric acid esters. J Invest Dermatol 121:1383 ^1388, 2003
P
soriasis is a widespread chronic in£ammatory skin dis-
order a¡ecting approximately 1.5% to 2% of the Eur-
opean population. Although the etiology of psoriasis is
still unknown, recent experimental ¢ndings point to-
ward a T cell-mediated disorder that may result from
(auto-)antigen-speci¢c activation in people with a genetic sus-
ceptibility (Christophers et al, 1999).
When psoriatic lesions are widespread and frequently relap-
sing, this results in a severe impairment of life quality and daily
living activities that makes systemic treatment necessary. In 1959,
the German chemist Schweckendiek ¢rst reported about a bene-
¢cial e¡ect of fumaric acid in the systemic treatment of psoriasis.
He su¡ered from this disease himself and hypothesized that dis-
turbances in the citrate cycle might result in the clinical appear-
ance of psoriatic lesions. He developed a mixture of di¡erent
fumaric acid esters (FAE) with an improved e⁄cacy and bioavail-
ibility compared to free fumaric acid (Schweckendiek, 1959).
Since then, FAE have been used by a number of physicians,
mainly in Germany and the Netherlands. In 1994 a de¢ned mix-
ture of FAE was registered in Germany under the brand name
Fumaderm for treatment of severe psoriasis. The main ingredient
of this mixture is dimethylfumarate (DMF); the other compo-
nents are Zn, Ca, and Mg salts of monoethylfumarate. Clinical
e⁄cacy of FAE have been proven in a randomized, double-blind,
placebo-controlled trial (Altmeyer et al, 1994) and in an open
multicenter study (Mrowietz et al, 1997). After a 16-wk treatment
period 70% of the patients completed the study showing a mean
reduction of the psoriasis area and severity index of 75% (Mro-
wietz et al, 1997). In recent years, many investigations have been
performed to de¢ne the mode of action of FAE in the treatment
of psoriasis and experimental ¢ndings indicate the involvement
of immunomodulating e¡ects (Mrowietz et al, 1999).
Monomethylfumarate (MHF), the hydrolysis product of DMF,
was demonstrated to modulate cytokine expression in primed
human CD4-positive T cells in favor of the production of inter-
leukins (IL)-4 and -5 without a¡ecting secretion of interferon-g
thus shifting the Th1-type immune response present in psoriasis
toward a Th2-like pattern (De Jong et al, 1996).
A characteristic clinical observation during FAE therapy is a
decrease in peripheral blood leukocyte numbers, which is mainly
due to a reduced number of T cells. Long-term observations of
human peripheral CD4- and CD8-positive lymphocyte subsets
showed an equal decrease of both subtypes (H˛xtermann et al,
1998). After cessation of treatment leukocyte/lymphocytes, num-
bers in the peripheral blood return to baseline values. The de-
crease of lymphocytes in the blood is paralleled by the dis-
appearance of cells of the in£ammatory in¢ltrate within psoriatic
plaques (Bacharach-Buhles et al, 1994).
By using the lymphohistiocytic cell line U937 it was shown
that DMF was able to induce apoptosis, whereas the Zn and Ca
salts of MEH were less e¡ective (Seb˛k et al, 2000). Subsequent
experiments revealed induction of apoptotic cell death in mono-
cyte-derived dendritic cells by DMF and that both DMF and
Ca-MHF concentration-dependently inhibited dendritic cell dif-
ferentiation (Zhu and Mrowietz, 2001).
Therefore, we investigated whether the decrease of T cells in
the blood and in the psoriasis plaque during FAE treatment may
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be due to the induction of apoptosis in these cells. For this pur-
pose human peripheral blood-stimulated and unstimulated Tcells
were treated with DMF and its main metabolite MHF, and in-
duction of apoptotic cell death was determined by two indepen-
dent methods. Additionally, the expression of the antiapoptotic
protein Bcl-2 was simultaneously determined.
MATERIALS AND METHODS
Isolation of T cells Puri¢ed human T cells were isolated from venous
blood of healthy donors using bu¡y coats provided by the Blood
Transfusion Center, University of Kiel. Bu¡y coats were processed by
using Ficoll separation of mononuclear cells. For the puri¢cation of T
cells, magnetic beads sorting was used employing a negative selection
technique (MACS system, Miltenyi Biotec, Bergisch Gladbach,
Germany). The purity as well as the number of recovered cells were
determined by a Coulter counter ZM connected to a channelyzer C256
(Beckman-Coulter, Krefeld, Germany). The Institutional Review Board
of the University of Kiel has approved the human studies and all clinical
investigations were conducted according to the Declaration of Helsinki
principles.
Determination of cell viability Viability of T cells was determined by
trypan blue dye exclusion.
Treatment of T cells with FAE FAE were from Merck (Darmstadt,
Germany). MHF was dissolved in medium RPMI 1640 and further used
in ¢nal concentrations of 1, 10, and 20 mg per mL. DMF was dissolved in
dimethyl sulfoxide (DMSO; Merck) at a concentration of 10 mg per mL.
DMF was further diluted to a ¢nal concentration of 1, 10, and 20 mg per mL
with RPMI 1640.
For control,T cells were incubated with DMSO at a ¢nal concentration
of 0.2% (vol/vol) corresponding to the highest DMF concentration used. T
cells without any addition of FAE or DMSO served as a medium control.
Stimulation of T cells T cells were seeded in six-well tissue culture
plates (Nunc,Wiesbaden, Germany) at a density of 6106 to 9106 cells
per well in supplemented RPMI 1640 with or without the addition of
FAE or DMSO or left with medium alone.
Three di¡erent ways of stimulation were used:
1. IL-2 (Proleukin, from Escherichia coli K12, Chiron, Emeryville, CA) at a
concentration of 200 U per mL for 48 h.
2. Solid-phase bound OKT3 antibodies: for this purpose tissue culture
plates were coated with a monoclonal anti-CD3 antibody (OKT3, Mur-
omonab, Othoclone/Janssen-Cilag, Neuss, Germany) at a concentration
of 10 mg per mL for 24 h at 371C in sodium-carbonate/sodium hydro-
gencarbonate bu¡er, pH 8. Before the cells were seeded onto the plate,
the antibody solution was discarded, and the wells washed three times
with PBS. Cells were incubated for 48 h.
3. T cells were incubated in OKT3-pre-treated plates together with IL-2
(200 U/mL) for 48 h.
For control, T cells were incubated in supplemented RPMI 1640 alone
for 48 h.
Determination of apoptosis To verify apoptotic cells death and to
discriminate apoptosis from necrosis two independent methods were used.
Expression of Apo2.7 To determine the induction of apoptosis in an
early stage, the expression of the mitochondrial membrane protein
Apo2.7 (7A6 antigen) was measured using a phycoerythrin-labeled
antibody as well as the respective isotype control (mouse IgG1-
phycoerythrin, Beckman-Coulter, Fullerton, CA) by £ow cytometry
(Zhang et al, 1996). CD4-, CD8-, and CD45RO-positive T cells were
gated, and Apo2.7-positive T cells were analyzed separately.
Analysis of DNA fragmentation The ¢nal step of apoptosis is
characterized by DNA fragmentation. This can be measured by terminal
deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL).
For this purpose,T cells were washed with PBS after culture and incubated
Figure1. Induction of Apo2.7 expression in puri¢ed human T cells by 1 to 20 lg per mL DMF or MHF after stimulation with IL-2, anti-
CD3-antibodies (OKT3), or both for 48 h as determined by £ow cytometry. For comparison T cells were treated with DMSO (0.2% vol/vol) or
with medium alone. Mean and SD, n¼ 5. po0.001; #po0.01.
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for 30 min in PBS with 4% paraformaldehyde. After cells were
washed with PBS and permeabilization with 0.1% Triton X-100 (Serva,
Hei-delberg, Germany), TUNEL was performed using the cell death
detection kit (Roche Diagnostics, Mannheim, Germany) following the
manufac-turer’s instruction. Labeled T cells were ¢nally resuspended in
PBS and analyzed by £ow cytometry. CD4-, CD8-, and CD45RO-
positive T cells were separately analyzed for terminal deoxynucleotide
transferase labeling.
Expression of Bcl-2 The presence of the antiapoptotic protein Bcl-2
was determined in IL-2-stimulated T cells with a speci¢c monoclonal
antibody (Dako, Hamburg, Germany). By using two-color £ow cyto-
metry, Bcl-2 and Apo2.7 expression was simultaneously measured.
Flow cytometry Flow cytometric analysis was performed by using a
Coulter Epics XL £ow cytometer together with system II software
(Beckman-Coulter).
Statistical analysis Data analysis was performed using the Student’s t
test for unpaired samples. DMF-treated cells were analyzed in reference to
the DMSO control, and cells were treated with medium served as the
reference for MHF treatment. A p value below 0.01 was considered
signi¢cant.
RESULTS
Viability of T cells Puri¢ed human T cells showed a viability
of 495% after 48 h of culture as judged by trypan blue dye
exclusion. Treatment of cells with FAE (up to 20 mg/mL) or
with DMSO (0.2%, vol/vol) did not alter viability of T cells.
Detection of apoptotic T cells by single color £ow
cytometry Figure 1 shows the expression of the apoptosis
related protein Apo2.7. In DMSO- or medium-treated cells, the
percentage of Apo2.7 labeling and therefore high £uorescent
T cells remained low (mean 19%).
When DMF was added to unstimulated T cells, signi¢cant
induction of Apo2.7 expression was seen at concentrations of
20 mg per mL only; MHF was without e¡ect. In T cells stimu-
lated with IL-2, OKT3, or a combination of both, DMF showed
a signi¢cant induction of apoptosis already at a concentration of
10 mg per mL. In IL-2-stimulated cells, MHF was ine¡ective
whereas in T cells stimulated with OKT3 or a combination of
OKT3 and IL-2 MHF could increase Apo2.7 expression already
at 20 mg per mL.
When apoptosis was determined by the TUNEL method to
detect DNA fragmentation as a late event in the apoptotic
cascade it could be shown that both HPMSO and MHF could
not enhance terminal deoxynucleotide transferase -labeling. In
IL-2-, OKT3-, or IL-2/OKT-3-stimulated T cells, DMF
increased DNA fragmentation at 20 mg per mL, whereas MHF
was without e¡ect (Fig 2). There was no di¡erence in the DMF-
mediated induction of Apo2.7 and DNA fragmentation in CD4-,
CD8-, or CD45RO-positive T cells (Fig 3).
To evaluate the time course of DMF and MHF on apoptosis,
human T cells were incubated with both compounds at a
concentration of 20 mg per mL which has been shown to
regularly induce Apo2.7 expression together with IL-2 for 15, 30,
60, 180, and 360 min, as well as for 24 h. The data displayed in
Fig 4 show a clear concentration- and time-dependent increase
in Apo2.7 expression for T cells treated with DMF, but not,
however, for cells treated with MHF, with the solvent DMSO,
or with medium alone.
Expression of Bcl-2 in IL-2-stimulated T cells In Fig 5 the
data of the simultaneous detection of Bcl-2 and Apo2.7 in FAE-
Figure 2. Induction of DNA fragmentation in puri¢ed human Tcells by 1 to 20 lg per mL DMF or MHF after stimulation with IL-2, anti-
CD3-antibodies (OKT3), or both for 48 h as determined by £ow cytometry using the TUNEL technique. For comparison T cells were treated
with DMSO (0.2% vol/vol) or with medium alone. Mean and SD, n¼ 5. po0.01; #po0.001.
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treated T cells stimulated for 48 h with IL-2 are shown. Only
DMF concentration-dependently decreased Bcl-2 expression
while increasing Apo2.7 expression. MHF and the solvent
DMSO did not a¡ect Bcl-2.
DISCUSSION
The common pathogenetic concept of psoriasis emphasizes a
major role for T cells driving the psoriatic tissue reaction (Prinz,
2001). Activation of T cells involves antigen-presenting cells and
an antigen or autoantigen originated from bacteria or epidermal
proteins such as keratins which structural similarities to strepto-
cocci (Gudmundsdottir et al, 1999;Vollmer et al, 2001).
TargetingTcells proved to be a successful therapeutic approach
either speci¢cally by using anti-CD4 monoclonal antibodies or
by drugs like cyclosporine inhibiting mainly self-activation by
downregulating IL-2 production (Ellis et al, 1986; Nicholas et al,
1991; Prinz et al, 1991).
The Fumaderm combination (dimethyl fumarate and ethylhy-
drogen fumarate Ca, Mg, and Zn salts) has been marketed
in Germany for the treatment of psoriasis since authorization
approval in August 1994. New experimental data provide evi-
dence that these compounds possess potent immunomodulatory
Figure 3. Induction of Apo2.7 expression and DNA fragmentation in puri¢ed human Tcells by 1 to 20 lg/mL DMF or MHF after stimula-
tion with IL-2 for 48 h as determined by £ow cytometry. For comparison T cells were treated with DMSO (0.2% vol/vol) or with medium alone.
CD4- and CD8-positive T cells were analyzed separately. Mean and SD, n¼ 5. po0.01.
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functions. T cells and cells of the monocyte/macrophage lineage
seem to be the major targets of FAE activity. It was shown that
MHF, the main metabolite of DMF as the major ingredient in
the registered drug Fumaderm, is able to shift aTh1-like immune
response toward aTh2-like pattern by inducing secretion of IL-4,
IL-5 (De Jong et al, 1996), and IL-10 (Asadullah et al, 1997).
A clinical observation further highlights the fact that T cells
may in particular prone to the modulatory activity of FAE. During
treatment with the marketed FAE mixture a decrease of leukocytes
mainly attributed to a decrease in lymphocyte numbers in the
peripheral blood is frequently seen (De Jong et al, 1996). In parallel
to the decreased numbers of lymphocytes in the periphery, skin-
in¢ltrating T cells are diminished (H˛xtermann et al, 1998).
The aim of our study was to investigate whether DMF and its
metabolite MHF are able to regulate T cell numbers by interfer-
ence with cell survival mechanisms. Apoptosis was substantiated
by using two independent methods, by measuring the expression
of the early apoptotic marker Apo2.7 and by measuring DNA
fragmentation with the well-established TUNEL technique as
the end stage of the apoptotic cascade.
The data clearly show that DMF is a potent inducer of apopto-
tic cell death inTcells. This induction of apoptosis is meditated in
a concentration- and time-dependent fashion. Interestingly, early
apoptotic changes (expression of Apo2.7) were preferentially seen
in T cells activated with IL-2, anti-CD3 antibodies OKT3, or a
combination of both stimuli for 48 h in comparison to unstimu-
lated cells. MHF was without e¡ect under these experimental
conditions.
The results further demonstrated an increased DNA fragmen-
tation in DMF-treated cells as a marker of completion of the
whole apoptotic cascade. With the exception of IL-2/OKT3-
stimulated cells, MHF did not induce DNA fragmentation as
measured byTUNEL within 48 h. At the same time, expression
of the antiapoptotic protein Bcl-2 was found to be decreased in
DMF-treated T cells in a concentration-dependent fashion.
The induction of apoptosis by DMF has been shown pre-
viously in U937 cells, an undi¡erentiated monocytic cell line (Se-
b˛k et al, 2000). In human monocyte-derived dendritic cells,
DMF and MHF inhibited GM^CSF/IL-4-induced dendritic cell
di¡erentiation in a concentration-dependent fashion. At higher
concentrations, DMF, but not MHF, induced apoptosis in these
cells (Zhu and Mrowietz, 2001). In comparison to monocyte-
derived dendritic cells, DMF induced apoptosis in stimulated
T cells in a 10 times lower concentration.
It has recently been shown that DMF is a potent inhibitor of
the NF-kB-signaling pathway in human ¢broblasts, leading to a
signi¢cant inhibition of kB1/p50 in the nucleus with little in£u-
ence of DMF on IkBa, b, and e as well as on RelA/p65 or c-Rel
(Vandermeeren et al, 2001). These data were con¢rmed in human
endothelial cells where DMF inhibited tumor necrosis factor-
a-induced expression of E-selectin by inhibition of the NF-kB
pathway, which was due to an inhibition of nuclear entry of p65
(Loewe et al, 2001, 2002). There was no experimental evidence for
an inhibition of tumor necrosis factor-a-induced signaling down
to IkB because the IkBa phosphorylation and IkBa degradation
were not altered.
These data con¢rmed an earlier observation using human per-
ipheral blood mononuclear cells in which DMF inhibited lipopo-
lysaccharide-induced protein secretion of the NF-kB-dependent
chemokines IL-8, Mig, and IP-10 concentration-dependently
(Stoof et al, 2001). Furthermore, in human umbilical vein en-
dothelial cells DMF was able to block the tumor necrosis factor-
a-induced expression of adhesion molecules ICAM-1, VCAM-1,
as well as of E-selectin (Vandermeeren et al, 1997).
The NF-kB pathway not only plays a central role in regulating
cytokine production but also regulates cellular activation and
survival as well as responses of the innate and adaptive immune
system. Dendritic cell maturation is dependent on NF-kB trans-
location (Rescigno et al, 1998). Inhibition of this process blocked
maturation and downregulated the expression of class II antigens
as well as of costimulatory molecules. Interestingly,T cell survival
is also dependent on NF-kB activation. It was demonstrated that
inhibition of NF-kB translocation in resting T cells resulted in
the induction of apoptosis independent of activation of caspases-
1 and -3 (Kolenko et al, 1999). These data are in full accordance
with the results of our study showing that DMF, as an inhibitor
of NF-kB translocation, induced apoptosis in humanT cells.
In human B cells, inhibition of NF-kB led to a downregula-
tion in Bcl-2 (Bureau et al, 2002). Furthermore, the novel immu-
nosuppressant FTY270 induces Bcl-2-associated apoptosis in
Jurkat Tcells, which was paralleled by an upregulation of annexin
V and DNA fragmentation (Suzuki et al, 1996; Nagahara et al,
2002). In two recent reviews (Hildeman et al, 2002; Marsden and
Strasser, 2002), a link between the NF-kB pathway and apoptosis
related to modulation of protein of the Bcl-2 family for the elim-
ination of activated T cells was emphasized.
Induction of apoptosis inT cells proved to be at least one prin-
ciple of drugs with therapeutic e⁄cacy in psoriasis. Photoche-
motherapy resulted in apoptotic cell death of skin-in¢ltrating
lymphocytes within psoriatic lesions and was associated with a
decreased production of IL-2 and interferon-g whereas IL-4 se-
cretion was enhanced (Coven et al, 1999). Furthermore, metho-
trexate treatment led to apoptosis induction in T cells followed
by a decrease in tumor necrosis factor-a and interferon-g-produc-
tion but an upregulation of IL-4 (Genestier et al, 1998).
Both decreased production of Th1-type cytokines such as IL-2
and interferon-g together with an increased production of
the Th2-like mediator IL-4 have been demonstrated for MHF
Figure 4. Expression of Apo2.7 in puri¢ed human T cells treated
with DMF or MHF (both 20 lg/mL) and stimulated with IL-2 for
di¡erent time points. For comparisonT cells were treated with dimethyl
sulfoxide (DMSO, 0.2% v/v) or with medium alone. Mean and SD, n¼ 5.
Figure 5. Expression of Apo2.7 and Bcl-2 in puri¢ed human Tcells
treated with DMF or MHF (0.1^20 lg/mL) and stimulated with
IL-2 for 48 h as determined by two-color £ow cytometry. For com-
parison T cells were treated with DMSO (0.2% v/v) or with medium
alone. Mean and SD, n¼ 3.
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treatment of T cells (De Jong et al, 1996). The link between the
induction of apoptosis by DMF and the increased production of
IL-4 became of great importance as it was demonstrated that sys-
temic administration of recombinant IL-4 proved to be an e¡ec-
tive and well-tolerated measure for treating psoriasis (Ghoreschi
et al, 2003).
Taken together our data show that DMF is a potent inducer of
apoptosis in human T cells in a concentration- and time-depen-
dent manner. Activated cells seem more susceptible to DMF-
induced cell death compared to resting T cells. The induction of
apoptosis seems to be directly linked to the ability of DMF to
inhibit NF-kB translocation. This mode of action may at least in
part contribute to the clinical e⁄cacy of FAE in the treatment of
psoriasis.
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